The IMT in our patient was negative for ALK-1, which has been reported in up to 87.5% of IMTs, whereas ALK-1 was found to be negative in sarcomatoid carcinoma, leiomyosarcoma and neurofibroma [13], but such reactivity does not appear to correlate with the prognosis of IMTs. This evidence concerns the gene ALK and sarcomatoid carcinoma.